Profil bibliographique

Hiroki Hara

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

37Publications signalées

256Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesEsophageal Cancer Research and TreatmentCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Les publications récentes

Accès ouvert 2025 article OpenAlex

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma

Yoshihiko Aoki, Izuma Nakayama, Y Komura, Masashi Wakabayashi et autres

jp (code pays fourni par la source)

1 citation ESMO Gastrointestinal Oncology

Accès ouvert 2025 article OpenAlex

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Sun Young Rha, Lucjan Wyrwicz, Nina Karaseva, Hisateru Yasui et autres

jp, de, kr, us, cl, pl, it, ru (code pays fourni par la source)

42 citations Journal of Clinical Oncology

Accès ouvert 2024 article OpenAlex

Impact of time from diagnosis to endoscopic submucosal dissection on curability in superficial esophageal squamous cell carcinoma

Daiki Sato, Maasa Sasabe, Tomohiro Mitsui, Yasuaki Furue et autres

jp (code pays fourni par la source)

1 citation DEN Open

Accès ouvert 2024 article OpenAlex

396. SHORT-TERM REVIEW: REAL-WORD EXPERIENCE OF PEMBROLIZUMAB AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Takako Yoshii, Hiroki Hara, Naoki Takahashi, Tomohiro Matsushima et autres

jp (code pays fourni par la source)

0 citations Diseases of the Esophagus

Accès ouvert 2024 article OpenAlex

518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

K. Yamazaki, Yosuke Kito, H. Shoji, Takeshi Yamada et autres

jp (code pays fourni par la source)

0 citations Annals of Oncology

2024 article OpenAlex

Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial

Chikatoshi Katada, Akira Yokoyama, Akinori Watanabe, Hiroki Hara et autres

jp, gb (code pays fourni par la source)

9 citations International Journal of Radiation Oncology*Biology*Physics

Accès ouvert 2024 article OpenAlex

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, Maria Passhak et autres

jp, cn, es, il, tw, us, tr, dk, ca, kr, gb, ar, au, ru, de (code pays fourni par la source)

89 citations Journal of Clinical Oncology

Accès ouvert 2024 article OpenAlex

500TiP An open label phase Ib/II study of trastuzumab deruxtecan (T-DXd) in combination with nivolumab and CAPOX for patients with HER2-low expressing gastroesophageal adenocarcinoma (EPOC2203)

Yoshihiko Aoki, Izuma Nakayama, S. Fukuoka, Hirokazu Shoji et autres

jp (code pays fourni par la source)

4 citations Annals of Oncology

Accès ouvert 2024 article OpenAlex

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Yuko Kitagawa, Satoru Matsuda, Takuji Gotoda, Ken Kato et autres

jp, nl, de, gb, us, sg, ch, kr, cn, it, se, hk, my, au (code pays fourni par la source)

24 citations Gastric Cancer

Accès ouvert 2024 conference-abstract OpenAlex

A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Daisuke Kotani, Kensei Yamaguchi, Ken Kato, Hiroki Hara et autres

jp, us (code pays fourni par la source)

10 citations Journal of Clinical Oncology

Accès ouvert 2023 article OpenAlex

LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)

Shigenori Kadowaki, Daisuke Sakai, Ryohei Kawabata, Hiroki Hara et autres

jp (code pays fourni par la source)

7 citations Annals of Oncology

Accès ouvert 2023 conference-abstract OpenAlex

P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

Takeshi Yamada, Yosuke Kito, Kazuko Sakai, Kazuto Nishio et autres

jp (code pays fourni par la source)

1 citation Annals of Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.